No products in the cart.
Pre-made Astegolimab benchmark antibody ( Whole mAb, anti-IL1RL1/ST2 therapeutic antibody, Anti-DER4/FIT-1/IL33R/T1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-033
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Astegolimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-33, an epithelial-derived “alarmin.” Astegolimab, a human IgG2 mAb, selectively inhibits the IL-33 receptor, ST2.
| Products Name (INN Index) | Pre-Made Astegolimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody |
|---|---|
| INN Name | Astegolimab |
| Target | IL1RL1 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Amgen,Genentech,University of Leicester |
| Conditions Approved | NA |
| Conditions Active | Allergic asthma,Atopic dermatitis,Chronic obstructive pulmonary disease |
| Conditions Discontinued | Asthma,Rhinosinusitis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL1RL1/ST2 |
| Package |
Previous slide
Next slide
